Biophytis To Present Positive Phase 2-3 COVA Study Results at ERS 2023 21st Lung Science Conference

(24/7 MARKET NEWS) – Biophytis SA (NASDAQ: BPTS) stated that it’s presenting the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at this weekend’s European Respiratory Society 2023 21st Lung Science Conference.

Biophytis is trading at $0.61, up $0.11 (+22.50%), on 1.5 million premarket shares.

Its 52-week trading range is $0.3501 to $3.36. Its premarket high is $0.8527 and it made a big move last week, so trading above the 65-cent level in the regular session would be bullish.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist